Immune checkpoints A therapeutic target in triple negative breast cancer

被引：35

作者：

Chawla, Akhil ^{[1
]}

Philips, Anne V. ^{[1
]}

Alatrash, Gheath ^{[2
]}

Mittendorf, Elizabeth ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant & Cellular Therapy, Houston, TX 77030 USA

来源：

ONCOIMMUNOLOGY | 2014年 / 3卷 / 04期

关键词：

PD-L1; PI3K; triple negative breast cancer; biomarker; immunotherapy; IMMUNOTHERAPY; ANTIBODY; SAFETY;

D O I：

10.4161/onci.28325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

引用

页数：3

共 50 条

[1] Potential therapeutic target for triple-negative breast cancer
Gilbert, Judith A.
LANCET ONCOLOGY, 2012, 13 (08): : E330 - E330
[2] WNT PATHWAY AS THERAPEUTIC TARGET OF TRIPLE NEGATIVE BREAST CANCER (TNBC)
Huelsewig, C.
Goette, M.
Ruckert, C.
Buchweitz, O.
Kiesel, L.
Pusztai, L.
Liedtke, C.
ANNALS OF ONCOLOGY, 2012, 23 : 39 - 39
[3] Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer
Wali, Vikram B.
Patwardhan, Gauri A.
Hatzis, Christos
Pusztai, Lajos
CANCER RESEARCH, 2017, 77
[4] Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer
Weiner-Gorzel, K.
Murphy, M.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1875 (02):
[5] cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule, Patricia B.
Crown, John
O'Donovan, Norma
Duffy, Michael J.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) : 999 - 1009
[6] ADAM17: A new therapeutic target for triple negative breast cancer?
McGowan, P.
Mullooly, M.
Sukor, S.
O'Donovan, N.
Duffy, M. J.
EJC SUPPLEMENTS, 2010, 8 (07): : 47 - 47
[7] CHK1 AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
Quidville, V.
Albiges-Sauvin, L.
Goubar, A.
Scott, V.
Andre, F.
ANNALS OF ONCOLOGY, 2011, 22 : 51 - 52
[8] Cripto-1 as a novel therapeutic target for triple negative breast cancer
Castro, Nadia P.
Fedorova-Abrams, Natalie D.
Merchant, Anand S.
Rangel, Maria Cristina
Nagaoka, Tadahiro
Karasawa, Hideaki
Klauzinska, Malgorzata
Hewitt, Stephen M.
Biswas, Kajal
Sharan, Shyam K.
Salomon, David S.
ONCOTARGET, 2015, 6 (14) : 11910 - 11929
[9] Erk5 as a therapeutic target in triple negative breast cancer (TNBC)
Miranda, Mariska Sauzine
Al Ejeh, Fares
Shi, Wei
Simpson, Peter
Lakhani, Sunil
Khanna, Kum Kum
CANCER RESEARCH, 2015, 75
[10] m-Calpain, a new therapeutic target of triple negative breast cancer
Jeon, K-H.
Kwon, Y.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →